CN100563707C - 免疫系统的激活和抑制 - Google Patents
免疫系统的激活和抑制 Download PDFInfo
- Publication number
- CN100563707C CN100563707C CNB200610051522XA CN200610051522A CN100563707C CN 100563707 C CN100563707 C CN 100563707C CN B200610051522X A CNB200610051522X A CN B200610051522XA CN 200610051522 A CN200610051522 A CN 200610051522A CN 100563707 C CN100563707 C CN 100563707C
- Authority
- CN
- China
- Prior art keywords
- cell
- inhibitor
- psi
- antigen
- myd88
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000005764 inhibitory process Effects 0.000 title description 30
- 230000005934 immune activation Effects 0.000 title description 4
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 127
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 126
- 239000003112 inhibitor Substances 0.000 claims abstract description 88
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 46
- 239000013598 vector Substances 0.000 claims abstract description 23
- 206010011968 Decreased immune responsiveness Diseases 0.000 claims abstract description 14
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 claims abstract description 14
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 claims abstract description 4
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 claims abstract description 4
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 claims abstract 3
- 210000004443 dendritic cell Anatomy 0.000 claims description 256
- 210000004027 cell Anatomy 0.000 claims description 179
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 68
- 230000014509 gene expression Effects 0.000 claims description 63
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 230000000890 antigenic effect Effects 0.000 claims description 35
- 230000030741 antigen processing and presentation Effects 0.000 claims description 31
- 230000001939 inductive effect Effects 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 27
- 102000040430 polynucleotide Human genes 0.000 claims description 27
- 108091033319 polynucleotide Proteins 0.000 claims description 27
- 239000002157 polynucleotide Substances 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 229920001184 polypeptide Polymers 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 244000052769 pathogen Species 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 15
- 239000002243 precursor Substances 0.000 claims description 15
- 230000000692 anti-sense effect Effects 0.000 claims description 14
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims 6
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 6
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 4
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 3
- 241000713666 Lentivirus Species 0.000 claims 1
- 241001597008 Nomeidae Species 0.000 abstract description 54
- 239000012190 activator Substances 0.000 abstract description 18
- 239000002773 nucleotide Substances 0.000 abstract description 11
- 125000003729 nucleotide group Chemical group 0.000 abstract description 11
- 230000036039 immunity Effects 0.000 abstract description 9
- 239000002253 acid Substances 0.000 abstract description 8
- 150000007513 acids Chemical class 0.000 abstract description 5
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 abstract description 3
- 108060006687 MAP kinase kinase kinase Proteins 0.000 abstract description 3
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 abstract description 2
- 108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 95
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 75
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 75
- 210000001744 T-lymphocyte Anatomy 0.000 description 70
- 239000000427 antigen Substances 0.000 description 59
- 108091007433 antigens Proteins 0.000 description 59
- 102000036639 antigens Human genes 0.000 description 59
- 230000006870 function Effects 0.000 description 58
- 210000000612 antigen-presenting cell Anatomy 0.000 description 57
- 230000000694 effects Effects 0.000 description 43
- 238000011282 treatment Methods 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 35
- 208000015181 infectious disease Diseases 0.000 description 34
- 102000004127 Cytokines Human genes 0.000 description 31
- 108090000695 Cytokines Proteins 0.000 description 31
- 201000010099 disease Diseases 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 229960005486 vaccine Drugs 0.000 description 29
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000010276 construction Methods 0.000 description 22
- 241000700605 Viruses Species 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 230000008859 change Effects 0.000 description 20
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 108091034117 Oligonucleotide Proteins 0.000 description 19
- 238000012545 processing Methods 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 239000000284 extract Substances 0.000 description 18
- 210000002540 macrophage Anatomy 0.000 description 18
- 238000011160 research Methods 0.000 description 18
- 102000000588 Interleukin-2 Human genes 0.000 description 17
- 108010002350 Interleukin-2 Proteins 0.000 description 17
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 15
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 230000004936 stimulating effect Effects 0.000 description 15
- 102000008379 I-kappa B Proteins Human genes 0.000 description 14
- 108010021699 I-kappa B Proteins Proteins 0.000 description 14
- 108090000978 Interleukin-4 Proteins 0.000 description 14
- 238000013459 approach Methods 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 13
- 230000007246 mechanism Effects 0.000 description 13
- 239000012744 reinforcing agent Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 206010020751 Hypersensitivity Diseases 0.000 description 12
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 12
- 208000026935 allergic disease Diseases 0.000 description 12
- 230000007815 allergy Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 108010005774 beta-Galactosidase Proteins 0.000 description 11
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 10
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 238000001994 activation Methods 0.000 description 10
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000002502 liposome Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000012679 serum free medium Substances 0.000 description 10
- 230000008054 signal transmission Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000010370 Adenoviridae Infections Diseases 0.000 description 9
- 206010060931 Adenovirus infection Diseases 0.000 description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 9
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 9
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 9
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 9
- 210000005087 mononuclear cell Anatomy 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- 108091092562 ribozyme Proteins 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 8
- 238000011238 DNA vaccination Methods 0.000 description 8
- 108090001007 Interleukin-8 Proteins 0.000 description 8
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000005540 biological transmission Effects 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 108010065805 Interleukin-12 Proteins 0.000 description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 7
- -1 imino phenyl Chemical group 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 208000032839 leukemia Diseases 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000003308 immunostimulating effect Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 102100035793 CD83 antigen Human genes 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 5
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 5
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 5
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000003915 cell function Effects 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000000710 homodimer Substances 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000000527 lymphocytic effect Effects 0.000 description 5
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 101150053046 MYD88 gene Proteins 0.000 description 3
- 101710164423 Mitogen-activated protein kinase kinase kinase 1 Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000005859 cell recognition Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960000814 tetanus toxoid Drugs 0.000 description 3
- 230000017105 transposition Effects 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000008102 Ankyrins Human genes 0.000 description 2
- 108010049777 Ankyrins Proteins 0.000 description 2
- 101100152731 Arabidopsis thaliana TH2 gene Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000256135 Chironomus thummi Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000238710 Dermatophagoides Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 101150081923 IL4 gene Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 108010009489 Lysosomal-Associated Membrane Protein 3 Proteins 0.000 description 2
- 102100038213 Lysosome-associated membrane glycoprotein 3 Human genes 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 241000186362 Mycobacterium leprae Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101800001442 Peptide pr Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 241000785681 Sander vitreus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 2
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 2
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 2
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 102220469748 Voltage-dependent L-type calcium channel subunit beta-2_F56N_mutation Human genes 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 241000238565 lobster Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000010396 two-hybrid screening Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000005369 Alstonia scholaris Species 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 108020003566 Antisense Oligodeoxyribonucleotides Proteins 0.000 description 1
- 241000256836 Apis Species 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101100046775 Arabidopsis thaliana TPPA gene Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000238659 Blatta Species 0.000 description 1
- LZJRNLRASBVRRX-ZDUSSCGKSA-N Boldine Chemical compound CN1CCC2=CC(O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-ZDUSSCGKSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 241000238097 Callinectes sapidus Species 0.000 description 1
- 229940121926 Calpain inhibitor Drugs 0.000 description 1
- 102100035037 Calpastatin Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000255930 Chironomidae Species 0.000 description 1
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 1
- 102000035183 Clathrin adaptor proteins Human genes 0.000 description 1
- 108091005769 Clathrin adaptor proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102100021579 Enhancer of filamentation 1 Human genes 0.000 description 1
- 101710128765 Enhancer of filamentation 1 Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 101710100588 Erythroid transcription factor Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102100036089 Fascin Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 241000255896 Galleria mellonella Species 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 108700040486 I kappa B beta Proteins 0.000 description 1
- 101150016712 IKZF1 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 1
- 101710110357 Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- DAQAKHDKYAWHCG-UHFFFAOYSA-N Lactacystin Natural products CC(=O)NC(C(O)=O)CSC(=O)C1(C(O)C(C)C)NC(=O)C(C)C1O DAQAKHDKYAWHCG-UHFFFAOYSA-N 0.000 description 1
- 241000736227 Lucilia sericata Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
- 101710164353 Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000257159 Musca domestica Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 102100033457 NF-kappa-B inhibitor beta Human genes 0.000 description 1
- 102100033103 NF-kappa-B inhibitor delta Human genes 0.000 description 1
- 101710115380 NF-kappa-B inhibitor delta Proteins 0.000 description 1
- 102100033104 NF-kappa-B inhibitor epsilon Human genes 0.000 description 1
- 101710093997 NF-kappa-B inhibitor epsilon Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000238661 Periplaneta Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 102100022513 Selenocysteine lyase Human genes 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 241000254152 Sitophilus oryzae Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 102000003718 TNF receptor-associated factor 5 Human genes 0.000 description 1
- 108090000001 TNF receptor-associated factor 5 Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 108010060889 Toll-like receptor 1 Proteins 0.000 description 1
- 102000008229 Toll-like receptor 1 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241001593750 Turcica Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003293 antisense oligodeoxyribonucleotide Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 108010044208 calpastatin Proteins 0.000 description 1
- RINJLGGPXSDSFR-UHFFFAOYSA-N carbonodithioic s,s-acid;pyrrolidine Chemical class OC(S)=S.C1CCNC1 RINJLGGPXSDSFR-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000009028 cell transition Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 108091000099 cysteine desulfurase Proteins 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000004041 dendritic cell maturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000021995 interleukin-8 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- DAQAKHDKYAWHCG-RWTHQLGUSA-N lactacystin Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)[C@]1([C@@H](O)C(C)C)NC(=O)[C@H](C)[C@@H]1O DAQAKHDKYAWHCG-RWTHQLGUSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- IYSYLWYGCWTJSG-XFXZXTDPSA-N n-tert-butyl-1-phenylmethanimine oxide Chemical compound CC(C)(C)[N+](\[O-])=C\C1=CC=CC=C1 IYSYLWYGCWTJSG-XFXZXTDPSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000001586 pre-b-lymphocyte Anatomy 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 150000003953 γ-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/06—Uses of viruses as vector in vitro
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9930616.9 | 1999-12-24 | ||
| GBGB9930616.9A GB9930616D0 (en) | 1999-12-24 | 1999-12-24 | Activation and inhibition of the immune system |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008191050A Division CN1254272C (zh) | 1999-12-24 | 2000-12-22 | 免疫系统的激活和抑制 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1817367A CN1817367A (zh) | 2006-08-16 |
| CN100563707C true CN100563707C (zh) | 2009-12-02 |
Family
ID=10867023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200610051522XA Expired - Fee Related CN100563707C (zh) | 1999-12-24 | 2000-12-22 | 免疫系统的激活和抑制 |
| CNB008191050A Expired - Fee Related CN1254272C (zh) | 1999-12-24 | 2000-12-22 | 免疫系统的激活和抑制 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB008191050A Expired - Fee Related CN1254272C (zh) | 1999-12-24 | 2000-12-22 | 免疫系统的激活和抑制 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7915009B2 (enExample) |
| EP (2) | EP1852123A3 (enExample) |
| JP (1) | JP2003518507A (enExample) |
| CN (2) | CN100563707C (enExample) |
| AT (1) | ATE390929T1 (enExample) |
| AU (1) | AU781496B2 (enExample) |
| CA (1) | CA2394880A1 (enExample) |
| DE (1) | DE60038503T2 (enExample) |
| ES (1) | ES2302707T3 (enExample) |
| GB (1) | GB9930616D0 (enExample) |
| NZ (1) | NZ519438A (enExample) |
| WO (1) | WO2001047543A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9930616D0 (en) * | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| CN100421727C (zh) * | 2000-12-22 | 2008-10-01 | 玛蒂尔达和特伦斯·肯尼迪风湿病学信托学会 | 方法 |
| GB0116249D0 (en) * | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
| JP2003055202A (ja) * | 2001-08-15 | 2003-02-26 | Hiroyuki Hanai | 炎症性腸疾患の予防・治療剤 |
| CN1306964C (zh) * | 2002-05-29 | 2007-03-28 | 安琪士摩奇株式会社 | 治疗和预防炎症性疾病的诱饵组合物 |
| AU2002953094A0 (en) * | 2002-12-04 | 2002-12-19 | The University Of Queensland | Immunomodulating compositions, processes for their production and uses therefor |
| US20060257380A1 (en) * | 2002-09-19 | 2006-11-16 | Inst.Nat. De La Sante Et De La Recherche MED | Use of sirnas for gene silencing in antigen presenting cells |
| EP2933334B1 (en) * | 2003-02-18 | 2019-09-18 | Baylor College of Medicine | Induced activation in dendritic cells |
| US20050147608A1 (en) * | 2003-05-08 | 2005-07-07 | Beth Israel Deaconess Medical Center, Inc. | Novel regulatory mechanisms of NF-kappaB |
| TWI487535B (zh) | 2004-11-30 | 2015-06-11 | Centocor Inc | 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途 |
| CN100418532C (zh) * | 2005-06-17 | 2008-09-17 | 吕志民 | 治疗多种疾病的NF-κB化合物抑制剂 |
| WO2007001487A2 (en) * | 2005-06-23 | 2007-01-04 | Baylor College Of Medicine | Modulation of negative immune regulators and applications for immunotherapy |
| US20080311552A1 (en) * | 2005-09-20 | 2008-12-18 | London Health Sciences Centre Research, Inc. | Use of Sirnas in Organ Storage/Reperfusion Solutions |
| WO2007051164A2 (en) | 2005-10-27 | 2007-05-03 | Centocor, Inc. | Toll like receptor 3 modulators, methods and uses |
| CN101240271B (zh) * | 2006-08-28 | 2012-08-29 | 长春华普生物技术有限公司 | Toll样受体调节性寡核苷酸及其用途 |
| CA2702340C (en) * | 2006-10-12 | 2014-12-16 | The University Of Queensland | Compositions and methods for modulating immune responses |
| US8691210B2 (en) * | 2006-10-19 | 2014-04-08 | David M Spencer | Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof |
| WO2008080195A1 (en) * | 2006-12-29 | 2008-07-10 | The University Of Queensland | Compositions and methods for treating or preventing unwanted immune responses |
| ES2633470T3 (es) | 2008-09-22 | 2017-09-21 | Baylor College Of Medicine | Métodos y composiciones de generación de una respuesta inmune mediante la inducción de CD40 y adaptadores de receptores de reconocimiento de patrones |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| CN103889461B (zh) * | 2011-07-18 | 2016-11-09 | 肯塔基大学研究基金会 | 保护细胞免于alu-rna诱导的变性和用于保护细胞的抑制剂 |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| KR20150131218A (ko) | 2013-03-14 | 2015-11-24 | 벨리쿰 파마슈티컬스, 인크. | T 세포 증식의 제어 방법 |
| US9913882B2 (en) | 2013-06-05 | 2018-03-13 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| JP6876434B2 (ja) * | 2013-09-12 | 2021-05-26 | アイカーン スクール オブ メディシン アット マウント サイナイ | 蛍光タンパク質に特異的なｔ細胞受容体を有する遺伝子導入動物の作製方法 |
| CN106132423B (zh) | 2014-02-14 | 2020-07-31 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
| US20150342961A1 (en) * | 2014-06-03 | 2015-12-03 | Hai-Hui Xue | Use of prostaglandin e1 (pge1) and misoprostol for treating chronic myelogenous/myeloid leukemia (cml) |
| JP6868554B2 (ja) | 2014-09-02 | 2021-05-12 | ベリカム ファーマシューティカルズ， インコーポレイテッド | ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激 |
| EP3215522B1 (en) | 2014-11-03 | 2021-12-01 | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | T cell receptors directed against bob1 and uses thereof |
| KR102656470B1 (ko) | 2014-12-10 | 2024-04-09 | 리전츠 오브 더 유니버스티 오브 미네소타 | 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기 |
| US10420836B2 (en) | 2015-10-08 | 2019-09-24 | Emory University | Methods of immunizing a subject and compositions related thereto |
| MA56038B1 (fr) | 2019-05-31 | 2024-11-29 | Janssen Pharmaceutica Nv | Inhibiteurs à petite molécule de kinase induisant nf-kb |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410516B1 (en) * | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| US5116742A (en) * | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US5149796A (en) * | 1989-08-31 | 1992-09-22 | City Of Hope | Chimeric DNA-RNA catalytic sequences |
| CA2073045C (en) | 1989-11-03 | 2007-05-22 | Malcolm L. Gefter | A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor |
| US5180818A (en) * | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
| WO1992007573A1 (en) | 1990-10-31 | 1992-05-14 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
| WO1994024281A1 (en) | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| CA2105595A1 (en) * | 1992-09-23 | 1994-03-24 | Ramaswamy Narayanan | Antisense polynucleotides |
| US5951988A (en) * | 1993-03-30 | 1999-09-14 | University Of Saskatchewan | Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods |
| US5405941A (en) * | 1993-04-15 | 1995-04-11 | National Jewish Center For Immunology And Respiratory Medicine | MEKK protein, capable of phosphorylating MEK |
| ATE204300T1 (de) | 1994-05-13 | 2001-09-15 | Biovation Ltd | Zielzellen-bindende chimäre peptide |
| NZ290089A (en) | 1994-07-27 | 1999-05-28 | Queensland Inst Med Res | Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines |
| US5597898A (en) * | 1995-02-15 | 1997-01-28 | Yale University | NF-κB activation regulatory protein, IκB-β |
| AU6181196A (en) * | 1995-06-29 | 1997-01-30 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal mast cell stabilizers |
| EP0779361A3 (en) * | 1995-12-15 | 1999-11-10 | F. Hoffmann-La Roche Ag | Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof |
| UA71889C2 (uk) * | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
| CA2262006A1 (en) * | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| CA2262906C (en) | 1996-08-12 | 2006-10-31 | Celgene Corporation | Novel immunotherapeutic agents and their use in the reduction of cytokine levels |
| WO1998008955A1 (en) * | 1996-08-26 | 1998-03-05 | Signal Pharmaceuticals, Inc. | Stimulus-inducible i (kappa)b kinase [ikk] signalsome |
| US5891924A (en) * | 1996-09-26 | 1999-04-06 | Research Development Foundation | Curcumin (diferuloylmethane) inhibition of NFκB activation |
| EP0946725B1 (en) * | 1996-12-23 | 2011-01-26 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| US6924308B1 (en) * | 1997-07-30 | 2005-08-02 | Howard L. Elford | Therapeutic process for inhibiting NF-κB |
| US5952483A (en) * | 1997-07-31 | 1999-09-14 | Smithkline Beecham Corporation | Human IκB-β |
| EP0897009A3 (en) * | 1997-08-04 | 1999-06-09 | Smithkline Beecham Plc | HKABY60 polypeptides |
| JPH1171278A (ja) * | 1997-09-01 | 1999-03-16 | Kanegafuchi Chem Ind Co Ltd | 転写因子ＮＦ−κＢ活性化阻害剤 |
| GB9719238D0 (en) | 1997-09-11 | 1997-11-12 | Mathilda & Terence Kennedy Ins | Viral infection of cells |
| US6503184B1 (en) * | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| US5965421A (en) * | 1997-11-26 | 1999-10-12 | Human Genome Sciences, Inc. | Human IRAK-2 |
| AU2294899A (en) * | 1998-02-19 | 1999-09-06 | Peter Bromley | Stress promoter control of therapeutic genes in gene therapy: compositions and methods |
| JP2002513552A (ja) * | 1998-05-06 | 2002-05-14 | フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー | ＮＦ−κＢ活性化の新規な阻害剤 |
| HUP0102782A3 (en) * | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| AU3755800A (en) * | 1999-03-15 | 2000-10-04 | Introgen Therapeutics, Inc. | Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
| GB9930616D0 (en) | 1999-12-24 | 2000-02-16 | Mathilda & Terence Kennedy Ins | Activation and inhibition of the immune system |
| GB0005345D0 (en) * | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| CN100421727C (zh) * | 2000-12-22 | 2008-10-01 | 玛蒂尔达和特伦斯·肯尼迪风湿病学信托学会 | 方法 |
| GB0116249D0 (en) * | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
-
1999
- 1999-12-24 GB GBGB9930616.9A patent/GB9930616D0/en not_active Ceased
-
2000
- 2000-12-22 AU AU22062/01A patent/AU781496B2/en not_active Ceased
- 2000-12-22 CN CNB200610051522XA patent/CN100563707C/zh not_active Expired - Fee Related
- 2000-12-22 CA CA002394880A patent/CA2394880A1/en not_active Abandoned
- 2000-12-22 DE DE60038503T patent/DE60038503T2/de not_active Expired - Lifetime
- 2000-12-22 ES ES00985660T patent/ES2302707T3/es not_active Expired - Lifetime
- 2000-12-22 EP EP07014428A patent/EP1852123A3/en not_active Withdrawn
- 2000-12-22 EP EP00985660A patent/EP1244466B1/en not_active Expired - Lifetime
- 2000-12-22 JP JP2001548135A patent/JP2003518507A/ja active Pending
- 2000-12-22 CN CNB008191050A patent/CN1254272C/zh not_active Expired - Fee Related
- 2000-12-22 WO PCT/GB2000/004925 patent/WO2001047543A2/en not_active Ceased
- 2000-12-22 AT AT00985660T patent/ATE390929T1/de not_active IP Right Cessation
- 2000-12-22 US US10/168,805 patent/US7915009B2/en not_active Expired - Fee Related
- 2000-12-22 NZ NZ519438A patent/NZ519438A/en not_active IP Right Cessation
-
2007
- 2007-12-06 US US11/987,956 patent/US20080124322A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1817367A (zh) | 2006-08-16 |
| CA2394880A1 (en) | 2001-07-05 |
| AU781496B2 (en) | 2005-05-26 |
| DE60038503T2 (de) | 2009-04-30 |
| US20080124322A1 (en) | 2008-05-29 |
| EP1852123A3 (en) | 2008-09-10 |
| ES2302707T3 (es) | 2008-08-01 |
| DE60038503D1 (de) | 2008-05-15 |
| CN1434718A (zh) | 2003-08-06 |
| CN1254272C (zh) | 2006-05-03 |
| JP2003518507A (ja) | 2003-06-10 |
| GB9930616D0 (en) | 2000-02-16 |
| US20030153518A1 (en) | 2003-08-14 |
| NZ519438A (en) | 2004-03-26 |
| EP1244466B1 (en) | 2008-04-02 |
| ATE390929T1 (de) | 2008-04-15 |
| AU2206201A (en) | 2001-07-09 |
| EP1244466A2 (en) | 2002-10-02 |
| WO2001047543A3 (en) | 2002-01-17 |
| WO2001047543A2 (en) | 2001-07-05 |
| US7915009B2 (en) | 2011-03-29 |
| EP1852123A2 (en) | 2007-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100563707C (zh) | 免疫系统的激活和抑制 | |
| Miranda-Hernandez et al. | Role of toll-like receptors in multiple sclerosis | |
| US20220175830A1 (en) | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer | |
| JP7320947B2 (ja) | 新規な免疫原性ＣＤ１ｄ結合ペプチド | |
| US20020131953A1 (en) | In situ langerhans cell vaccine | |
| Wells et al. | Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity | |
| Cui et al. | Immunotherapy of established tumors using bone marrow transplantation with antigen gene–modified hematopoietic stem cells | |
| Peng et al. | Treatment of subcutaneous tumor with adoptively transferred T cells | |
| CN110575537A (zh) | Dc疫苗和nkg2a拮抗剂的组合物及在抗乳腺癌或肝癌中的应用 | |
| CN102216448A (zh) | Foxp3+天然杀伤t细胞及免疫相关疾病的治疗 | |
| US20150044244A1 (en) | Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases | |
| JP2008543301A (ja) | フィブロネクチンのｅｄａドメインの使用を基にした剤および方法 | |
| CA2274837A1 (en) | Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene | |
| Kreiter et al. | FLT3 ligand as a molecular adjuvant for naked RNA vaccines | |
| CN109414023A (zh) | 用嵌合脊髓灰质炎病毒激活抗原呈递细胞的组合物和方法 | |
| RU2447899C2 (ru) | Композиция для лечения гепатита с и способ лечения гепатита с | |
| CN101580539A (zh) | 一种诱导cd4+cd25+调节性t细胞的多肽及应用 | |
| Wurzenberger et al. | Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo | |
| WO2006072946A2 (en) | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation | |
| CN111566122A (zh) | 产生用于调控免疫的肽、多肽或细胞的方法 | |
| Tamburini et al. | IL-6-inducing whole yeast-based immunotherapy directly controls IL-12-dependent CD8 T-cell responses | |
| CN117645974A (zh) | 新冠病毒m蛋白限制性表位多肽致敏的树突状细胞及其应用 | |
| CN1370077A (zh) | 抗胞内病原体的疫苗 | |
| CN118086212A (zh) | 新冠病毒表位多肽致敏的树突状细胞及其应用 | |
| EP4469079A1 (en) | Coronavirus antigen variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMAT Free format text: FORMER OWNER: SYNOVIS LTD. Effective date: 20070518 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070518 Address after: London, England Applicant after: Synovis Ltd. Address before: London, England Applicant before: Synovis Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091202 Termination date: 20131222 |